Symeres and Axxam Name Russell Thomas as CSO

Symeres, a contract research, development and manufacturing organization (CRDMO), and Axxam, a provider of biology-driven discovery services, have both appointed Russell Thomas, Ph.D., as Chief Scientific Officer to drive a joint collaboration between the companies that combines the unique R&D services offering of both organizations.

The appointment aims to strengthen the scientific leadership of both Symeres and Axxam as they continue to build a closely connected, science-led offering for pharmaceutical and biotechnology partners. By bringing together the complementary capabilities of both organizations, customers can receive support across integrated discovery and development programs. The integrated solutions offered span all the way from target assessment, screening and testing, lead identification and optimization all the way to development candidate nomination and IND ready packages.

As CSO, Thomas will help shape and execute the scientific strategy of Symeres and Axxam, as well as working closely with scientific and commercial teams across both companies. His role will include supporting the development of integrated client solutions, connecting scientific capabilities, and identifying opportunities to further strengthen the combined discovery and development capabilities.

Experience

Thomas returns to Symeres after a year supporting growing biotech and biomaterials companies. As well as his experience at Axxam and Symeres, he has held scientific and leadership positions at organizations including GSK, Evotec, Siena Biotech, and Proteros. His experience spanning the entire R&D value chain will be a significant advantage to customers discovery and development programs.

“Returning as Chief Scientific Officer feels very exciting as it connects two parts of a story. Having spent important parts of my career at both Symeres and Axxam, I’m excited to help bring together expert led complementary science, strong transatlantic teams and a shared mindset to support partners and projects in a truly integrated way,” said Thomas.

Thomas first joined Symeres in January 2020 as Head of Business Development and later served as Chief Scientific Officer. During his tenure, he played a key role in developing strategic customer relationships and strengthening the company’s scientific profile across the global pharmaceutical and biotechnology sectors.

Before joining Symeres, Thomas served as Director of Discovery Research and later Director of Strategic Alliances at Axxam. He helped establish and manage the integrated medicinal chemistry relationship with Symeres, giving him a deep understanding of both organizations ensuring he is aligned to the scientific and cultural foundations customers value.